A detailed history of Kcm Investment Advisors LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Kcm Investment Advisors LLC holds 22,098 shares of BMY stock, worth $1.29 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
22,098
Previous 22,978 3.83%
Holding current value
$1.29 Million
Previous $954,000 19.81%
% of portfolio
0.04%
Previous 0.03%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$39.66 - $51.75 $34,900 - $45,540
-880 Reduced 3.83%
22,098 $1.14 Million
Q2 2024

Jul 29, 2024

SELL
$40.25 - $52.99 $95,593 - $125,851
-2,375 Reduced 9.37%
22,978 $954,000
Q1 2024

May 07, 2024

SELL
$47.98 - $54.4 $1.28 Million - $1.45 Million
-26,681 Reduced 51.28%
25,353 $1.37 Million
Q4 2023

Feb 13, 2024

SELL
$48.48 - $57.85 $668,248 - $797,404
-13,784 Reduced 20.94%
52,034 $2.67 Million
Q3 2023

Nov 08, 2023

SELL
$57.89 - $64.73 $156,303 - $174,771
-2,700 Reduced 3.94%
65,818 $3.82 Million
Q2 2023

Aug 09, 2023

SELL
$63.71 - $70.74 $1.32 Million - $1.46 Million
-20,656 Reduced 23.16%
68,518 $4.38 Million
Q1 2023

May 09, 2023

BUY
$65.71 - $74.53 $553,343 - $627,617
8,421 Added 10.43%
89,174 $6.18 Million
Q4 2022

Jan 31, 2023

SELL
$68.48 - $81.09 $157,504 - $186,507
-2,300 Reduced 2.77%
80,753 $5.81 Million
Q3 2022

Nov 10, 2022

SELL
$0.13 - $76.84 $22 - $13,139
-171 Reduced 0.21%
83,053 $5.9 Million
Q2 2022

Aug 15, 2022

SELL
$72.62 - $79.98 $319,600 - $351,991
-4,401 Reduced 5.02%
83,224 $6.41 Million
Q1 2022

May 13, 2022

SELL
$61.48 - $73.72 $181,857 - $218,063
-2,958 Reduced 3.27%
87,625 $6.4 Million
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $251,095 - $292,718
-4,682 Reduced 4.91%
90,583 $5.65 Million
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $54,732 - $64,111
-925 Reduced 0.96%
95,265 $5.64 Million
Q2 2021

Oct 21, 2021

SELL
$61.91 - $67.42 $513,853 - $559,586
-8,300 Reduced 7.94%
96,190 $6.43 Million
Q2 2021

Aug 12, 2021

SELL
$61.91 - $67.42 $74,849 - $81,510
-1,209 Reduced 1.14%
104,490 $6.98 Million
Q1 2021

May 13, 2021

SELL
$59.34 - $66.74 $177,189 - $199,285
-2,986 Reduced 2.75%
105,699 $6.67 Million
Q4 2020

Feb 19, 2021

SELL
$57.74 - $65.43 $244,990 - $277,619
-4,243 Reduced 3.76%
108,685 $6.74 Million
Q3 2020

Nov 16, 2020

SELL
$57.43 - $63.64 $738,951 - $818,855
-12,867 Reduced 10.23%
112,928 $6.81 Million
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $415,809 - $486,122
7,585 Added 6.42%
125,795 $7.4 Million
Q1 2020

Apr 27, 2020

SELL
$46.4 - $67.43 $306,008 - $444,700
-6,595 Reduced 5.28%
118,210 $6.59 Million
Q4 2019

Feb 18, 2020

SELL
$49.21 - $64.19 $451,550 - $589,007
-9,176 Reduced 6.85%
124,805 $8.01 Million
Q3 2019

Nov 15, 2019

SELL
$42.77 - $50.71 $949,536 - $1.13 Million
-22,201 Reduced 14.21%
133,981 $6.79 Million
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $529,282 - $585,271
-11,862 Reduced 7.06%
156,182 $7.08 Million
Q1 2019

May 16, 2019

SELL
$45.12 - $53.8 $430,805 - $513,682
-9,548 Reduced 5.38%
168,044 $8.02 Million
Q4 2018

Feb 12, 2019

SELL
$48.76 - $63.23 $302,945 - $392,847
-6,213 Reduced 3.38%
177,592 $9.23 Million
Q3 2018

Nov 07, 2018

SELL
$55.19 - $62.25 $450,515 - $508,146
-8,163 Reduced 4.25%
183,805 $0
Q2 2018

Aug 10, 2018

SELL
$50.53 - $62.98 $4.27 Million - $5.32 Million
-84,456 Reduced 30.55%
191,968 $10.6 Million
Q1 2018

May 09, 2018

SELL
$59.92 - $68.98 $366,770 - $422,226
-6,121 Reduced 2.17%
276,424 $17.5 Million
Q4 2017

Feb 22, 2018

SELL
$59.94 - $65.35 $592,806 - $646,311
-9,890 Reduced 3.38%
282,545 $17.3 Million
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $16.2 Million - $18.6 Million
292,435
292,435 $18.6 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Kcm Investment Advisors LLC Portfolio

Follow Kcm Investment Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kcm Investment Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kcm Investment Advisors LLC with notifications on news.